Drug intelligence / Profile preview

levodopa + carbidopa (CP-012)

Development stage: Unknown
Lead developer: Contera Pharma
Modality: Small Molecules
Administration: Oral

Overview

CP-012 is a novel delayed-release, dual-pulse oral tablet formulation containing levodopa and carbidopa. It is designed to address nocturnal immobility and morning akinesia in Parkinson’s disease patients by delivering these agents at times when motor symptoms are most problematic. The formulation utilizes BDD Pharma's OralogiK™ timed release technology to provide pulsatile delivery of the active ingredients. The drug is currently in Phase 1 clinical trials for this indication[2][3].

Targets

DDC (Aromatic L-amino acid decarboxylase)

Beyond the preview

Go deeper on levodopa + carbidopa (CP-012).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on levodopa + carbidopa (CP-012).

Explore the full profile